392 related articles for article (PubMed ID: 24874015)
41. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
[TBL] [Abstract][Full Text] [Related]
42. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
Ergul M; Bakar-Ates F
Chem Biol Interact; 2020 Dec; 332():109288. PubMed ID: 33075310
[TBL] [Abstract][Full Text] [Related]
43. Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.
Simioni C; Neri LM; Tabellini G; Ricci F; Bressanin D; Chiarini F; Evangelisti C; Cani A; Tazzari PL; Melchionda F; Pagliaro P; Pession A; McCubrey JA; Capitani S; Martelli AM
Leukemia; 2012 Nov; 26(11):2336-42. PubMed ID: 22614243
[TBL] [Abstract][Full Text] [Related]
44. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
Deng Z; Chen G; Liu S; Li Y; Zhong J; Zhang B; Li L; Huang H; Wang Z; Xu Q; Deng X
Eur J Med Chem; 2020 Nov; 206():112697. PubMed ID: 32814244
[TBL] [Abstract][Full Text] [Related]
45. Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.
Hartsink-Segers SA; Exalto C; Allen M; Williamson D; Clifford SC; Horstmann M; Caron HN; Pieters R; Den Boer ML
Haematologica; 2013 Oct; 98(10):1539-46. PubMed ID: 23753023
[TBL] [Abstract][Full Text] [Related]
46. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation.
Li L; Wang X; Chen J; Ding H; Zhang Y; Hu TC; Hu LH; Jiang HL; Shen X
Acta Pharmacol Sin; 2009 Oct; 30(10):1443-53. PubMed ID: 19801998
[TBL] [Abstract][Full Text] [Related]
47. Cucurbitacin-I inhibits Aurora kinase A, Aurora kinase B and survivin, induces defects in cell cycle progression and promotes ABT-737-induced cell death in a caspase-independent manner in malignant human glioma cells.
Premkumar DR; Jane EP; Pollack IF
Cancer Biol Ther; 2015; 16(2):233-43. PubMed ID: 25482928
[TBL] [Abstract][Full Text] [Related]
48. Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target.
Huang TC; Cutler J; Bharne S; Zhong J; Weinstock D; Tyner J; Gojo I; Civin C; Pandey A
Leuk Lymphoma; 2015 May; 56(5):1524-7. PubMed ID: 25213184
[No Abstract] [Full Text] [Related]
49. Selective inhibition of Aurora A and B kinases effectively induces cell cycle arrest in t(8;21) acute myeloid leukemia.
Qi J; Gao X; Zhong X; Zhang N; Wang R; Zhang H; Pan T; Liu X; Yao Y; Wu Q; Niu M; Xu K
Biomed Pharmacother; 2019 Sep; 117():109113. PubMed ID: 31207577
[TBL] [Abstract][Full Text] [Related]
50. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
[TBL] [Abstract][Full Text] [Related]
51. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Gazi M; Moharram SA; Marhäll A; Kazi JU
Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
[TBL] [Abstract][Full Text] [Related]
52. Development of a Polo-like Kinase-1 Polo-Box Domain Inhibitor as a Tumor Growth Suppressor in Mice Models.
Gunasekaran P; Yim MS; Ahn M; Soung NK; Park JE; Kim J; Bang G; Shin SC; Choi J; Kim M; Kim HN; Lee YH; Chung YH; Lee K; EunKyeong Kim E; Jeon YH; Kim MJ; Lee KR; Kim BY; Lee KS; Ryu EK; Bang JK
J Med Chem; 2020 Dec; 63(23):14905-14920. PubMed ID: 33142063
[TBL] [Abstract][Full Text] [Related]
53. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
Münch C; Dragoi D; Frey AV; Thurig K; Lübbert M; Wäsch R; Bogatyreva L; Hauschke D; Lassmann S; Werner M; May AM
Leuk Res; 2015 Apr; 39(4):462-70. PubMed ID: 25697066
[TBL] [Abstract][Full Text] [Related]
54. Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy.
Valianou M; Cox AM; Pichette B; Hartley S; Paladhi UR; Astrinidis A
Cell Cycle; 2015; 14(3):399-407. PubMed ID: 25565629
[TBL] [Abstract][Full Text] [Related]
55. Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma.
Cheung AK; Ip JC; Lung HL; Wu JZ; Tsao SW; Lung ML
Mol Cancer Ther; 2013 Aug; 12(8):1393-401. PubMed ID: 23686835
[TBL] [Abstract][Full Text] [Related]
56. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
57. Preclinical evaluation of the Aurora kinase inhibitors AMG 900, AZD1152-HQPA, and MK-5108 on SW-872 and 93T449 human liposarcoma cells.
Noronha S; Alt LAC; Scimeca TE; Zarou O; Obrzut J; Zanotti B; Hayward EA; Pillai A; Mathur S; Rojas J; Salamah R; Chandar N; Fay MJ
In Vitro Cell Dev Biol Anim; 2018 Jan; 54(1):71-84. PubMed ID: 29197031
[TBL] [Abstract][Full Text] [Related]
58. Polo-like kinase 1 inhibitors, mitotic stress and the tumor suppressor p53.
Sanhaji M; Louwen F; Zimmer B; Kreis NN; Roth S; Yuan J
Cell Cycle; 2013 May; 12(9):1340-51. PubMed ID: 23574746
[TBL] [Abstract][Full Text] [Related]
59. Polo-like Kinase 1 as an emerging drug target: structure, function and therapeutic implications.
Shakeel I; Basheer N; Hasan GM; Afzal M; Hassan MI
J Drug Target; 2021 Feb; 29(2):168-184. PubMed ID: 32886539
[TBL] [Abstract][Full Text] [Related]
60. PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer.
De Martino D; Yilmaz E; Orlacchio A; Ranieri M; Zhao K; Di Cristofano A
Cancer Lett; 2018 Dec; 439():56-65. PubMed ID: 30243708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
